

## Short BIO Charlotte Teunissen

Charlotte Teunissen's mission is to improve care of patients with neurological diseases by developing body fluid biomarkers for diagnosis, stratification, prognosis and monitoring treatment responses. Studies of her research group cover the entire spectrum of biomarker development, starting with biomarker identification, followed by biomarker assay development and analytical validation, and extensive clinical validation to ultimately implement novel biomarkers in clinical practice. Charlotte has strong expertise with assay development on state of the art technologies, such as Quanterix ultrasensitive SimOA technology, and in implementation of *in vitro* diagnostic technologies for clinical routine lab analysis. She is responsible for the biobank of the Amsterdam Dementia Cohort (>5000 paired CSF and serum samples of dementia patients and controls, all deep phenotypes). She has an extensive track record in development of guidelines for biobanking and international collaboration for biomarker studies (e.g. Society for Neurochemistry and routine CSF analysis and the Alzheimer Association-Global Biomarker Standardization consortium).